 Connection
Search Results to
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
| Property | Value |
|
information resource reference
|
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
|
|
label
|
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
|
|
|